- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02416687
Etonogestrel Implant and Postpartum Insertion
Immediate Post-partum Initiation of Etonogestrel-releasing Implant: a Randomized Controlled Trial on Breastfeeding Impact
Study Overview
Detailed Description
What is known already: The ENG implant inserted immediately postpartum reduces the risk of pregnancy recurrence, especially in vulnerable populations. A limitation to recommending this practice universally is the low quality of evidence on the effect of the ENG implant on breastfeeding when inserted immediately postpartum. This study is the first assessing the impact of inserting the ENG implant immediately postpartum on the amount of milk using the gold standard method for this purpose.
Study design, size, duration: This randomized, single-blind and controlled clinical trial evaluated 24 postpartum women and their NBs and was conducted at the Women's Health Reference Center of Ribeirão Preto, Brazil. The mother-NB pairs were evaluated for six weeks postpartum.
Participants/materials, setting, methods: Twenty-four mother-NB pairs were randomized into two groups: a) Implant group: ENG-releasing implant inserted within 48 h after delivery and b) Control group: absence of contraceptive method for six weeks after delivery. Anthropometric assessments and breastfeeding questionnaires were conducted at 4-time points of the 6-week monitoring period (at study admission and on the 14th, 29th and 43rd days after randomization). Saliva samples were collected from the mother-NB pairs prior to deuterium (D2O) dose administration. Totals of 5 g and 10 g D2O were orally administered to the postpartum women on the day of randomization (day 0) and the 29th study day, respectively. New saliva samples were collected on days 1, 2, 3, 4, 13 and 14 following intake of each D2O dose. The D2O isotope ratio was assessed in saliva samples using mass spectrometry to estimate the volume of breast milk ingested by the NB (daily average expressed as mL/day).
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
SP
-
Ribeirão Preto, SP, Brazil, 14049-900
- Hospital das Clinica de Ribeirao Preto
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Postpartum women aged 18 years or older who agreed to use the ENG implant as a contraceptive method,
- Body mass index (BMI) <30 kg/m2,
- Women without contraindication to breastfeeding,
- Women whose newborns were healthy, without malformations, born at term (gestational age ≥ 37 weeks), with appropriate weight for gestational age and with normal sucking ability, were included.
- The subjects had to live in Ribeirão Preto and to have breastfed a child from a previous delivery for at least 3 months.
Exclusion Criteria:
- Tobacco smokers, drug addicts or alcoholics,
- Women with educational levels lower than 5 years,
- Women with clinical conditions considered category 3 and 4 for implant use (except insertion immediately postpartum) by the WHO (World Health Organization, 2009),
- Women with histories of psychiatric illness,
- Women using medications that could alter the concentration of etonogestrel,
- Women with known allergies to the local anesthetic lidocaine (used to place the implant),
- Women who wanted to keep their cyclic menstrual bleeding
Study Plan
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Implanon®
Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) was inserted in the first 48 h postpartum
|
Postpartum women into whom the etonogestrel-releasing contraceptive implant was inserted in the first 48 h postpartum
Other Names:
|
NO_INTERVENTION: Control group
Postpartum women who used no contraceptive method in the first six weeks after delivery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
breast milk intake
Time Frame: Six weeks after delivery
|
The primary outcome was the amount of breast milk intake by the NBs through breastfeeding in the first six weeks after delivery
|
Six weeks after delivery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exclusive breastfeeding
Time Frame: Six weeks after delivery
|
Rate of exclusive breastfeeding
|
Six weeks after delivery
|
Newborn weight
Time Frame: Six weeks after delivery
|
Weight gain by newborns in six weeks after delivery
|
Six weeks after delivery
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 62798
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contraception
-
Virginia Commonwealth UniversityCompletedPregnancy Related | Contraception | Contraception Behavior | Contraception Use
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Medical University of South CarolinaSociety of Family PlanningCompletedContraception | Contraception BehaviorUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedFemale Contraception | ContraceptionUnited States, Israel
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Janssen Pharmaceutica N.V., BelgiumCompleted
-
University of California, San FranciscoAgency for Healthcare Research and Quality (AHRQ); Essential Access HealthNot yet recruitingContraception | Contraception Behavior | Reproductive BehaviorUnited States
Clinical Trials on Implanon®
-
Organon and CoCompleted
-
Duke UniversityCompletedContinuation Rate of Contraceptive ImplantUnited States
-
Organon and CoCompleted
-
University of PittsburghMakerere UniversityCompletedHIV | ContraceptionUganda
-
University of the PhilippinesOrganonNot yet recruitingEndometrial Hyperplasia Without Atypia
-
University Hospital, GenevaTerminatedContraception | Progestogen Adverse Reaction
-
University of North Carolina, Chapel HillCompletedContraception | Postpartum | AdolescenceUnited States
-
Catherine Anne ChappellUniversity of Nebraska; Infectious Disease Institute, Kampala, UgandaCompletedHIV/AIDS | ContraceptionUganda